Lymphedema Diagnostic Market Size by Technology, End User, Disease Type, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2029
3.8%
CAGR (2023-2029)
33.18 USD Mn.
Market Size
319
Report Pages
126
Market Tables
Overview
Lymphedema Diagnostic market is expected to reach US$ 43.09 Mn. at a CAGR of 3.8% during the forecast period 2029.
Lymphedema is a chronic and progressive disorder resulting from impaired lymphatic system function. In developed countries, upper extremity lymphedema is mainly the consequence of breast cancer surgery in which axillary lymph node dissection and radiation alter upper extremity lymphatic flow.
To know about the Research Methodology :- Request Free Sample Report
Diagnosis of lymphedema is made clinically. Although there is no unique sign or criteria for defining LE, the diagnosis is usually made clinically by a thorough evaluation and physical examination.
Family history is important in the diagnosis of primary LE. The main symptoms are chronic swelling, progressive atrophic skin changes, and recurrent infections. It is important to identify whether the swelling is transient or persistent.
The lymphedema diagnostics market in developing regions is witnessing a growth in terms of its adoption rate, due to increasing cases of lymphedema, rising prevalence of cancer, and advancement in diagnostic methods. Prevalence estimates for lymphedema are relatively high, yet its prevalence is likely underestimated. Attempts to identify the population impact of lymphedema are hampered by the fact that this chronic, debilitating disease is frequently under-recognized or misdiagnosed. Recent prevalence estimates suggest that chronic edema is present between 1.33 per thousand5 to 1.44 per thousand.
The growing prevalence of lymphedema and cancer is a major driver for the market to elevate. Moreover, technological advancements in diagnostic equipment by industries are also expected to boost the market. The increase in advancements is encouraging stakeholders to invest more in the market. Increasing government funds and grants by private organizations are increasing the revenue share of the market. Lymphedema can also be cancer-associated such as lung cancer and breast cancer. The increasing cases of cancer-associated lymphedema are also expected to propel the market. Primary lymphedema is considered to be in around 1.3 children per 10,000 births in North America. Moreover, the population aged over the age of 65 years of age is known to be significantly affected.
However, the high cost of diagnostic imaging systems, limited supply of helium, and the short half-life of radiopharmaceuticals are restraining the market growth.
The report contains a detailed analysis of the Strengths, Weaknesses, and opportunities of the key players operating in the Global Lymphedema Diagnostic market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers, and the key challenges.
The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.
Segment Analysis
The Lymphoscintigraphy segment is expected held the largest share of xx% in 2021 and is expected to grow at a CAGR of xx% in the forecast period.
Lymphoscintigraphy is a special type of nuclear medicine imaging that provides pictures called scintigrams of the lymphatic system. Nuclear medicine imaging uses small amounts of radioactive material to diagnose, evaluate or treat a variety of diseases. These include many types of cancers, heart disease, gastrointestinal, endocrine, or neurological disorders, and other abnormalities. Because nuclear medicine exams can pinpoint molecular activity, they have the potential to identify disease in its earliest stages. They can also show whether a patient is responding to treatment. Easy reproducibility of this technique is considered to be a major factor driving the market. Also, Lymphoscintigraphy does not directly affect the lymphatic vascular epithelium is a key factor for this segment to elevate.
By disease type, cancer is the fastest-growing segment. The increasing prevalence of cancer-associated lymphedema cases is helping the market to grow at a faster pace. Also, awareness about the early diagnosis is associated with market growth.
Based on end-users, the hospital segment is accounted for the largest share of the market in 2021. The large share of this segment can be attributed to a large number of lymphedema diagnostic procedures performed in hospitals, the growing adoption of minimum invasive procedures, and the rising adoption of advanced imaging procedures to improve workflow efficiency in hospitals.
The Global Lymphedema Diagnostic market is segmented based on-
Scope of the Global Lymphedema Diagnostic market : Inquire before buying
| Global Lymphedema Diagnostic Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 33.18 Mn. |
| Forecast Period 2023 to 2029 CAGR: | 3.8% | Market Size in 2029: | US $ 43.09 Mn. |
| Segments Covered: | by Technology | Lymphoscintigraphy X-ray Lymphography Computed Tomography Magnetic Resonance Imaging Fluorescein Sodium Micro lymphangiography Ultrasound Imaging ICG Lymphography Bio impedance Analysis Near-infrared Fluorescence Imaging |
|
| by End User | Hospitals Diagnostic Centers Research and Academic Centers Others |
||
| by Disease Type | Cardiovascular Diseases Cancer Inflammatory Diseases Others |
||
Lymphedema Diagnostic market Regional Insights
North America accounted for the largest share of xx% in 2022, the reason being the rising prevalence of cancer-associated lymphedema. Growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field have boosted the market growth. Rising adoption of technologically advanced diagnostic imaging systems for lymphedema is rapidly growing the market.
The Asia Pacific is also expected to witness significant growth during the forecast period due to the increasing geriatric population and rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected to drive the market demand.
Key Players operating the Global Lymphedema Diagnostic market
1. Siemens Healthineers
2. GE Healthcare
3. Stryker Corporation
4. Mindray Medical International, Ltd.
5. Philips
6. Canon, Inc
7. Shimazdu Corporation
8. Fluoptics United Imaging Healthcare Co, Ltd
9. Hitachi Ltd
10.Esaote
11.SpA
12.Neusoft Corporation
13.Mindray Medical International Ltd
14.Mitaka, Inc
15.Curadel, LLC
16.ImpediMed Ltd
Frequently Asked Questions:
1. Which region has the largest share in Global Lymphedema Diagnostic market?
Ans: North America region holds the highest share in 2022.
2. What is the growth rate of Global Lymphedema Diagnosticmarket?
Ans: The Global Lymphedema Diagnostic Market is growing at a CAGR of 3.8 % during forecasting period 2023-2029.
3. What is scope of the Global Lymphedema Diagnostic market report?
Ans: Global Remote Healthcare Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. What is the study period of this market?
Ans: The Global Lymphedema Diagnostic Market is studied from 2022 to 2029.
Table of Contents
Global Lymphedema Diagnostic market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: LYMPHEDEMA DIAGNOSTIC Market Size, By Market Value (US$ Mn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global LYMPHEDEMA DIAGNOSTIC Market Analysis and Forecast
6.1. LYMPHEDEMA DIAGNOSTIC Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global LYMPHEDEMA DIAGNOSTIC Market Analysis and Forecast, By Technology
7.1. Introduction and Definition
7.2. Key Findings
7.3. LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology
7.4. LYMPHEDEMA DIAGNOSTIC Market Size (US$ Mn) Forecast, By Technology
7.5. LYMPHEDEMA DIAGNOSTIC Market Analysis, By Technology
7.6. LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis, By Technology
8. Global LYMPHEDEMA DIAGNOSTIC Market Analysis and Forecast, By Disease Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type
8.4. LYMPHEDEMA DIAGNOSTIC Market Size (US$ Mn) Forecast, By Disease Type
8.5. LYMPHEDEMA DIAGNOSTIC Market Analysis, By Disease Type
8.6. LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis, By Disease Type
9. Global LYMPHEDEMA DIAGNOSTIC Market Analysis and Forecast By End-user
9.1. Introduction and Definition
9.2. Key Findings
9.3. LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user
9.4. LYMPHEDEMA DIAGNOSTIC Market Size (US$ Mn) Forecast, By End-user
9.5. LYMPHEDEMA DIAGNOSTIC Market Analysis, By End-user
9.6. LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis, By End-user
10. Global LYMPHEDEMA DIAGNOSTIC Market Analysis, By Region
10.1. LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Region
10.2. LYMPHEDEMA DIAGNOSTIC Market Size (US$ Mn) Forecast, By Region
10.3. LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis, By Region
11. North America LYMPHEDEMA DIAGNOSTIC Market Analysis
11.1. Key Findings
11.2. North America LYMPHEDEMA DIAGNOSTIC Market Overview
11.3. North America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology
11.4. North America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
11.4.1. Lymphoscintigraphy
11.4.2. X-ray Lymphography
11.4.3. Computed Tomography
11.4.4. Magnetic Resonance Imaging
11.4.5. Fluorescein Sodium Micro lymphangiography
11.4.6. Ultrasound Imaging
11.4.7. ICG Lymphography
11.4.8. Bio impedance Analysis
11.4.9. Near-infrared Fluorescence Imaging
11.5. North America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type
11.6. North America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
11.6.1. Cardiovascular Diseases
11.6.2. Cancer
11.6.3. Inflammatory Diseases
11.6.4. Others
11.7. North America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user
11.8. North America LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
11.8.1. Hospitals
11.8.2. Diagnostic Centers
11.8.3. Research and Academic Centers
11.8.4. Others
11.9. North America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country
11.10. North America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country
11.10.1. U.S.
11.10.2. Canada
11.10.3. Mexico
11.11. North America LYMPHEDEMA DIAGNOSTIC Market Analysis, By Country
11.12. U.S. LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
11.12.1. Lymphoscintigraphy
11.12.2. X-ray Lymphography
11.12.3. Computed Tomography
11.12.4. Magnetic Resonance Imaging
11.12.5. Fluorescein Sodium Micro lymphangiography
11.12.6. Ultrasound Imaging
11.12.7. ICG Lymphography
11.12.8. Bio impedance Analysis
11.12.9. Near-infrared Fluorescence Imaging
11.13. U.S. LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
11.13.1. Cardiovascular Diseases
11.13.2. Cancer
11.13.3. Inflammatory Diseases
11.13.4. Others
11.14. U.S. LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
11.14.1. Hospitals
11.14.2. Diagnostic Centers
11.14.3. Research and Academic Centers
11.14.4. Others
11.15. Canada LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
11.15.1. Lymphoscintigraphy
11.15.2. X-ray Lymphography
11.15.3. Computed Tomography
11.15.4. Magnetic Resonance Imaging
11.15.5. Fluorescein Sodium Micro lymphangiography
11.15.6. Ultrasound Imaging
11.15.7. ICG Lymphography
11.15.8. Bio impedance Analysis
11.15.9. Near-infrared Fluorescence Imaging
11.16. Canada LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
11.16.1. Cardiovascular Diseases
11.16.2. Cancer
11.16.3. Inflammatory Diseases
11.16.4. Others
11.17. Canada LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
11.17.1. Hospitals
11.17.2. Diagnostic Centers
11.17.3. Research and Academic Centers
11.17.4. Others
11.18. Mexico LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
11.18.1. Lymphoscintigraphy
11.18.2. X-ray Lymphography
11.18.3. Computed Tomography
11.18.4. Magnetic Resonance Imaging
11.18.5. Fluorescein Sodium Micro lymphangiography
11.18.6. Ultrasound Imaging
11.18.7. ICG Lymphography
11.18.8. Bio impedance Analysis
11.18.9. Near-infrared Fluorescence Imaging
11.19. Mexico LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
11.19.1. Cardiovascular Diseases
11.19.2. Cancer
11.19.3. Inflammatory Diseases
11.19.4. Others
11.20. Mexico LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
11.20.1. Hospitals
11.20.2. Diagnostic Centers
11.20.3. Research and Academic Centers
11.20.4. Others
11.21. North America LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis
11.21.1. By Technology
11.21.2. By Disease Type
11.21.3. By End-user
11.22. PEST Analysis
11.23. Key Trends
11.24. Key Developments
12. Europe LYMPHEDEMA DIAGNOSTIC Market Analysis
12.1. Key Findings
12.2. Europe LYMPHEDEMA DIAGNOSTIC Market Overview
12.3. Europe LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology
12.4. Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.4.1. Lymphoscintigraphy
12.4.2. X-ray Lymphography
12.4.3. Computed Tomography
12.4.4. Magnetic Resonance Imaging
12.4.5. Fluorescein Sodium Micro lymphangiography
12.4.6. Ultrasound Imaging
12.4.7. ICG Lymphography
12.4.8. Bio impedance Analysis
12.4.9. Near-infrared Fluorescence Imaging
12.5. Europe LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type
12.6. Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.6.1. Cardiovascular Diseases
12.6.2. Cancer
12.6.3. Inflammatory Diseases
12.6.4. Others
12.7. Europe LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user
12.8. Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.8.1. Hospitals
12.8.2. Diagnostic Centers
12.8.3. Research and Academic Centers
12.8.4. Others
12.9. Europe LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country
12.10. Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Sweden
12.10.7. CIS countries
12.10.8. Rest of Europe
12.11. Germany LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.11.1. Lymphoscintigraphy
12.11.2. X-ray Lymphography
12.11.3. Computed Tomography
12.11.4. Magnetic Resonance Imaging
12.11.5. Fluorescein Sodium Micro lymphangiography
12.11.6. Ultrasound Imaging
12.11.7. ICG Lymphography
12.11.8. Bio impedance Analysis
12.11.9. Near-infrared Fluorescence Imaging
12.12. Germany LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.12.1. Cardiovascular Diseases
12.12.2. Cancer
12.12.3. Inflammatory Diseases
12.12.4. Others
12.13. Germany LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.13.1. Hospitals
12.13.2. Diagnostic Centers
12.13.3. Research and Academic Centers
12.13.4. Others
12.14. U.K. LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.14.1. Lymphoscintigraphy
12.14.2. X-ray Lymphography
12.14.3. Computed Tomography
12.14.4. Magnetic Resonance Imaging
12.14.5. Fluorescein Sodium Micro lymphangiography
12.14.6. Ultrasound Imaging
12.14.7. ICG Lymphography
12.14.8. Bio impedance Analysis
12.14.9. Near-infrared Fluorescence Imaging
12.15. U.K. LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.15.1. Cardiovascular Diseases
12.15.2. Cancer
12.15.3. Inflammatory Diseases
12.15.4. Others
12.16. U.K. LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.16.1. Hospitals
12.16.2. Diagnostic Centers
12.16.3. Research and Academic Centers
12.16.4. Others
12.17. France LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.17.1. Lymphoscintigraphy
12.17.2. X-ray Lymphography
12.17.3. Computed Tomography
12.17.4. Magnetic Resonance Imaging
12.17.5. Fluorescein Sodium Micro lymphangiography
12.17.6. Ultrasound Imaging
12.17.7. ICG Lymphography
12.17.8. Bio impedance Analysis
12.17.9. Near-infrared Fluorescence Imaging
12.18. France LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.18.1. Cardiovascular Diseases
12.18.2. Cancer
12.18.3. Inflammatory Diseases
12.18.4. Others
12.19. France LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.19.1. Hospitals
12.19.2. Diagnostic Centers
12.19.3. Research and Academic Centers
12.19.4. Others
12.20. Italy LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.20.1. Lymphoscintigraphy
12.20.2. X-ray Lymphography
12.20.3. Computed Tomography
12.20.4. Magnetic Resonance Imaging
12.20.5. Fluorescein Sodium Micro lymphangiography
12.20.6. Ultrasound Imaging
12.20.7. ICG Lymphography
12.20.8. Bio impedance Analysis
12.20.9. Near-infrared Fluorescence Imaging
12.21. Italy LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.21.1. Cardiovascular Diseases
12.21.2. Cancer
12.21.3. Inflammatory Diseases
12.21.4. Others
12.22. Italy LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.22.1. Hospitals
12.22.2. Diagnostic Centers
12.22.3. Research and Academic Centers
12.22.4. Others
12.23. Spain LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.23.1. Lymphoscintigraphy
12.23.2. X-ray Lymphography
12.23.3. Computed Tomography
12.23.4. Magnetic Resonance Imaging
12.23.5. Fluorescein Sodium Micro lymphangiography
12.23.6. Ultrasound Imaging
12.23.7. ICG Lymphography
12.23.8. Bio impedance Analysis
12.23.9. Near-infrared Fluorescence Imaging
12.24. Spain LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.24.1. Cardiovascular Diseases
12.24.2. Cancer
12.24.3. Inflammatory Diseases
12.24.4. Others
12.25. Spain LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.25.1. Hospitals
12.25.2. Diagnostic Centers
12.25.3. Research and Academic Centers
12.25.4. Others
12.26. Sweden LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.26.1. Lymphoscintigraphy
12.26.2. X-ray Lymphography
12.26.3. Computed Tomography
12.26.4. Magnetic Resonance Imaging
12.26.5. Fluorescein Sodium Micro lymphangiography
12.26.6. Ultrasound Imaging
12.26.7. ICG Lymphography
12.26.8. Bio impedance Analysis
12.26.9. Near-infrared Fluorescence Imaging
12.27. Sweden LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.27.1. Cardiovascular Diseases
12.27.2. Cancer
12.27.3. Inflammatory Diseases
12.27.4. Others
12.28. Sweden LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.28.1. Hospitals
12.28.2. Diagnostic Centers
12.28.3. Research and Academic Centers
12.28.4. Others
12.29. CIS countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.29.1. Lymphoscintigraphy
12.29.2. X-ray Lymphography
12.29.3. Computed Tomography
12.29.4. Magnetic Resonance Imaging
12.29.5. Fluorescein Sodium Micro lymphangiography
12.29.6. Ultrasound Imaging
12.29.7. ICG Lymphography
12.29.8. Bio impedance Analysis
12.29.9. Near-infrared Fluorescence Imaging
12.30. CIS countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.30.1. Cardiovascular Diseases
12.30.2. Cancer
12.30.3. Inflammatory Diseases
12.30.4. Others
12.31. CIS countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.31.1. Hospitals
12.31.2. Diagnostic Centers
12.31.3. Research and Academic Centers
12.31.4. Others
12.32. Rest of Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
12.32.1. Lymphoscintigraphy
12.32.2. X-ray Lymphography
12.32.3. Computed Tomography
12.32.4. Magnetic Resonance Imaging
12.32.5. Fluorescein Sodium Micro lymphangiography
12.32.6. Ultrasound Imaging
12.32.7. ICG Lymphography
12.32.8. Bio impedance Analysis
12.32.9. Near-infrared Fluorescence Imaging
12.33. Rest of Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
12.33.1. Cardiovascular Diseases
12.33.2. Cancer
12.33.3. Inflammatory Diseases
12.33.4. Others
12.34. Rest of Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
12.34.1. Hospitals
12.34.2. Diagnostic Centers
12.34.3. Research and Academic Centers
12.34.4. Others
12.35. Europe LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis
12.35.1. By Disease Type
12.35.2. By Technology
12.35.3. By End-user
12.36. PEST Analysis
12.37. Key Trends
12.38. Key Developments
13. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Analysis
13.1. Key Findings
13.2. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Overview
13.3. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology
13.4. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
13.4.1. Lymphoscintigraphy
13.4.2. X-ray Lymphography
13.4.3. Computed Tomography
13.4.4. Magnetic Resonance Imaging
13.4.5. Fluorescein Sodium Micro lymphangiography
13.4.6. Ultrasound Imaging
13.4.7. ICG Lymphography
13.4.8. Bio impedance Analysis
13.4.9. Near-infrared Fluorescence Imaging
13.5. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type
13.6. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
13.6.1. Cardiovascular Diseases
13.6.2. Cancer
13.6.3. Inflammatory Diseases
13.6.4. Others
13.7. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user
13.8. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
13.8.1. Hospitals
13.8.2. Diagnostic Centers
13.8.3. Research and Academic Centers
13.8.4. Others
13.9. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country
13.10. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. South Korea
13.10.5. Australia
13.10.6. ASEAN
13.10.7. Rest of Asia Pacific
13.11. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Analysis, By Country
13.12. China LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
13.12.1. Lymphoscintigraphy
13.12.2. X-ray Lymphography
13.12.3. Computed Tomography
13.12.4. Magnetic Resonance Imaging
13.12.5. Fluorescein Sodium Micro lymphangiography
13.12.6. Ultrasound Imaging
13.12.7. ICG Lymphography
13.12.8. Bio impedance Analysis
13.12.9. Near-infrared Fluorescence Imaging
13.13. China LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
13.13.1. Cardiovascular Diseases
13.13.2. Cancer
13.13.3. Inflammatory Diseases
13.13.4. Others
13.14. China LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
13.14.1. Hospitals
13.14.2. Diagnostic Centers
13.14.3. Research and Academic Centers
13.14.4. Others
13.15. India LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
13.15.1. Lymphoscintigraphy
13.15.2. X-ray Lymphography
13.15.3. Computed Tomography
13.15.4. Magnetic Resonance Imaging
13.15.5. Fluorescein Sodium Micro lymphangiography
13.15.6. Ultrasound Imaging
13.15.7. ICG Lymphography
13.15.8. Bio impedance Analysis
13.15.9. Near-infrared Fluorescence Imaging
13.16. India LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
13.16.1. Cardiovascular Diseases
13.16.2. Cancer
13.16.3. Inflammatory Diseases
13.16.4. Others
13.17. India LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
13.17.1. Hospitals
13.17.2. Diagnostic Centers
13.17.3. Research and Academic Centers
13.17.4. Others
13.18. Japan LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
13.18.1. Lymphoscintigraphy
13.18.2. X-ray Lymphography
13.18.3. Computed Tomography
13.18.4. Magnetic Resonance Imaging
13.18.5. Fluorescein Sodium Micro lymphangiography
13.18.6. Ultrasound Imaging
13.18.7. ICG Lymphography
13.18.8. Bio impedance Analysis
13.18.9. Near-infrared Fluorescence Imaging
13.19. Japan LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
13.19.1. Cardiovascular Diseases
13.19.2. Cancer
13.19.3. Inflammatory Diseases
13.19.4. Others
13.20. Japan LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
13.20.1. Hospitals
13.20.2. Diagnostic Centers
13.20.3. Research and Academic Centers
13.20.4. Others
13.21. South Korea LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
13.21.1. Lymphoscintigraphy
13.21.2. X-ray Lymphography
13.21.3. Computed Tomography
13.21.4. Magnetic Resonance Imaging
13.21.5. Fluorescein Sodium Micro lymphangiography
13.21.6. Ultrasound Imaging
13.21.7. ICG Lymphography
13.21.8. Bio impedance Analysis
13.21.9. Near-infrared Fluorescence Imaging
13.22. South Korea LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
13.22.1. Cardiovascular Diseases
13.22.2. Cancer
13.22.3. Inflammatory Diseases
13.22.4. Others
13.23. South Korea LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
13.23.1. Hospitals
13.23.2. Diagnostic Centers
13.23.3. Research and Academic Centers
13.23.4. Others
13.24. Australia LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
13.24.1. Lymphoscintigraphy
13.24.2. X-ray Lymphography
13.24.3. Computed Tomography
13.24.4. Magnetic Resonance Imaging
13.24.5. Fluorescein Sodium Micro lymphangiography
13.24.6. Ultrasound Imaging
13.24.7. ICG Lymphography
13.24.8. Bio impedance Analysis
13.24.9. Near-infrared Fluorescence Imaging
13.25. Australia LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
13.25.1. Cardiovascular Diseases
13.25.2. Cancer
13.25.3. Inflammatory Diseases
13.25.4. Others
13.26. Australia LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
13.26.1. Hospitals
13.26.2. Diagnostic Centers
13.26.3. Research and Academic Centers
13.26.4. Others
13.27. ASEAN LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
13.27.1. Lymphoscintigraphy
13.27.2. X-ray Lymphography
13.27.3. Computed Tomography
13.27.4. Magnetic Resonance Imaging
13.27.5. Fluorescein Sodium Micro lymphangiography
13.27.6. Ultrasound Imaging
13.27.7. ICG Lymphography
13.27.8. Bio impedance Analysis
13.27.9. Near-infrared Fluorescence Imaging
13.28. ASEAN LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
13.28.1. Cardiovascular Diseases
13.28.2. Cancer
13.28.3. Inflammatory Diseases
13.28.4. Others
13.29. ASEAN LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
13.29.1. Hospitals
13.29.2. Diagnostic Centers
13.29.3. Research and Academic Centers
13.29.4. Others
13.30. Rest of Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
13.30.1. Lymphoscintigraphy
13.30.2. X-ray Lymphography
13.30.3. Computed Tomography
13.30.4. Magnetic Resonance Imaging
13.30.5. Fluorescein Sodium Micro lymphangiography
13.30.6. Ultrasound Imaging
13.30.7. ICG Lymphography
13.30.8. Bio impedance Analysis
13.30.9. Near-infrared Fluorescence Imaging
13.31. Rest of Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
13.31.1. Cardiovascular Diseases
13.31.2. Cancer
13.31.3. Inflammatory Diseases
13.31.4. Others
13.32. Rest of Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
13.32.1. Hospitals
13.32.2. Diagnostic Centers
13.32.3. Research and Academic Centers
13.32.4. Others
13.33. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis
13.33.1. By Technology
13.33.2. By Disease Type
13.33.3. By End-user
13.34. PEST Analysis
13.35. Key Trends
13.36. Key Developments
14. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Analysis
14.1. Key Findings
14.2. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Overview
14.3. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology
14.4. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
14.4.1. Lymphoscintigraphy
14.4.2. X-ray Lymphography
14.4.3. Computed Tomography
14.4.4. Magnetic Resonance Imaging
14.4.5. Fluorescein Sodium Micro lymphangiography
14.4.6. Ultrasound Imaging
14.4.7. ICG Lymphography
14.4.8. Bio impedance Analysis
14.4.9. Near-infrared Fluorescence Imaging
14.5. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type
14.6. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
14.6.1. Cardiovascular Diseases
14.6.2. Cancer
14.6.3. Inflammatory Diseases
14.6.4. Others
14.7. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user
14.8. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
14.8.1. Hospitals
14.8.2. Diagnostic Centers
14.8.3. Research and Academic Centers
14.8.4. Others
14.9. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country
14.10. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country
14.10.1. GCC Countries
14.10.2. South Africa
14.10.3. Nigeria
14.10.4. Egypt
14.10.5. Rest of Middle East & Africa
14.11. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Analysis, By Country
14.12. GCC Countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
14.12.1. Lymphoscintigraphy
14.12.2. X-ray Lymphography
14.12.3. Computed Tomography
14.12.4. Magnetic Resonance Imaging
14.12.5. Fluorescein Sodium Micro lymphangiography
14.12.6. Ultrasound Imaging
14.12.7. ICG Lymphography
14.12.8. Bio impedance Analysis
14.12.9. Near-infrared Fluorescence Imaging
14.13. GCC Countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
14.13.1. Cardiovascular Diseases
14.13.2. Cancer
14.13.3. Inflammatory Diseases
14.13.4. Others
14.14. GCC Countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
14.14.1. Hospitals
14.14.2. Diagnostic Centers
14.14.3. Research and Academic Centers
14.14.4. Others
14.15. South Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
14.15.1. Lymphoscintigraphy
14.15.2. X-ray Lymphography
14.15.3. Computed Tomography
14.15.4. Magnetic Resonance Imaging
14.15.5. Fluorescein Sodium Micro lymphangiography
14.15.6. Ultrasound Imaging
14.15.7. ICG Lymphography
14.15.8. Bio impedance Analysis
14.15.9. Near-infrared Fluorescence Imaging
14.16. South Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
14.16.1. Cardiovascular Diseases
14.16.2. Cancer
14.16.3. Inflammatory Diseases
14.16.4. Others
14.17. South Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
14.17.1. Hospitals
14.17.2. Diagnostic Centers
14.17.3. Research and Academic Centers
14.17.4. Others
14.18. Nigeria LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
14.18.1. Lymphoscintigraphy
14.18.2. X-ray Lymphography
14.18.3. Computed Tomography
14.18.4. Magnetic Resonance Imaging
14.18.5. Fluorescein Sodium Micro lymphangiography
14.18.6. Ultrasound Imaging
14.18.7. ICG Lymphography
14.18.8. Bio impedance Analysis
14.18.9. Near-infrared Fluorescence Imaging
14.19. Nigeria LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
14.19.1. Cardiovascular Diseases
14.19.2. Cancer
14.19.3. Inflammatory Diseases
14.19.4. Others
14.20. Nigeria LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
14.20.1. Hospitals
14.20.2. Diagnostic Centers
14.20.3. Research and Academic Centers
14.20.4. Others
14.21. Egypt LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
14.21.1. Lymphoscintigraphy
14.21.2. X-ray Lymphography
14.21.3. Computed Tomography
14.21.4. Magnetic Resonance Imaging
14.21.5. Fluorescein Sodium Micro lymphangiography
14.21.6. Ultrasound Imaging
14.21.7. ICG Lymphography
14.21.8. Bio impedance Analysis
14.21.9. Near-infrared Fluorescence Imaging
14.22. Egypt LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
14.22.1. Cardiovascular Diseases
14.22.2. Cancer
14.22.3. Inflammatory Diseases
14.22.4. Others
14.23. Egypt LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
14.23.1. Hospitals
14.23.2. Diagnostic Centers
14.23.3. Research and Academic Centers
14.23.4. Others
14.24. Rest of Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
14.24.1. Lymphoscintigraphy
14.24.2. X-ray Lymphography
14.24.3. Computed Tomography
14.24.4. Magnetic Resonance Imaging
14.24.5. Fluorescein Sodium Micro lymphangiography
14.24.6. Ultrasound Imaging
14.24.7. ICG Lymphography
14.24.8. Bio impedance Analysis
14.24.9. Near-infrared Fluorescence Imaging
14.25. Rest of Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
14.25.1. Cardiovascular Diseases
14.25.2. Cancer
14.25.3. Inflammatory Diseases
14.25.4. Others
14.26. Rest of Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
14.26.1. Hospitals
14.26.2. Diagnostic Centers
14.26.3. Research and Academic Centers
14.26.4. Others
14.27. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis
14.27.1. By Technology
14.27.2. By Disease Type
14.27.3. By End-user
14.28. PEST Analysis
14.29. Key Trends
14.30. Key Developments
15. South America LYMPHEDEMA DIAGNOSTIC Market Analysis
15.1. Key Findings
15.2. South America LYMPHEDEMA DIAGNOSTIC Market Overview
15.3. South America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology
15.4. South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
15.4.1. Lymphoscintigraphy
15.4.2. X-ray Lymphography
15.4.3. Computed Tomography
15.4.4. Magnetic Resonance Imaging
15.4.5. Fluorescein Sodium Micro lymphangiography
15.4.6. Ultrasound Imaging
15.4.7. ICG Lymphography
15.4.8. Bio impedance Analysis
15.4.9. Near-infrared Fluorescence Imaging
15.5. South America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type
15.6. South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
15.6.1. Cardiovascular Diseases
15.6.2. Cancer
15.6.3. Inflammatory Diseases
15.6.4. Others
15.7. South America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user
15.8. South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
15.8.1. Hospitals
15.8.2. Diagnostic Centers
15.8.3. Research and Academic Centers
15.8.4. Others
15.9. South America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country
15.10. South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country
15.10.1. Brazil
15.10.2. Colombia
15.10.3. Argentina
15.10.4. Rest of South America
15.11. South America LYMPHEDEMA DIAGNOSTIC Market Analysis, By Country
15.12. Brazil LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
15.12.1. Lymphoscintigraphy
15.12.2. X-ray Lymphography
15.12.3. Computed Tomography
15.12.4. Magnetic Resonance Imaging
15.12.5. Fluorescein Sodium Micro lymphangiography
15.12.6. Ultrasound Imaging
15.12.7. ICG Lymphography
15.12.8. Bio impedance Analysis
15.12.9. Near-infrared Fluorescence Imaging
15.13. Brazil LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
15.13.1. Cardiovascular Diseases
15.13.2. Cancer
15.13.3. Inflammatory Diseases
15.13.4. Others
15.14. Brazil LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
15.14.1. Hospitals
15.14.2. Diagnostic Centers
15.14.3. Research and Academic Centers
15.14.4. Others
15.15. Colombia LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
15.15.1. Lymphoscintigraphy
15.15.2. X-ray Lymphography
15.15.3. Computed Tomography
15.15.4. Magnetic Resonance Imaging
15.15.5. Fluorescein Sodium Micro lymphangiography
15.15.6. Ultrasound Imaging
15.15.7. ICG Lymphography
15.15.8. Bio impedance Analysis
15.15.9. Near-infrared Fluorescence Imaging
15.16. Colombia LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
15.16.1. Cardiovascular Diseases
15.16.2. Cancer
15.16.3. Inflammatory Diseases
15.16.4. Others
15.17. Colombia LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
15.17.1. Hospitals
15.17.2. Diagnostic Centers
15.17.3. Research and Academic Centers
15.17.4. Others
15.18. Argentina LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
15.18.1. Lymphoscintigraphy
15.18.2. X-ray Lymphography
15.18.3. Computed Tomography
15.18.4. Magnetic Resonance Imaging
15.18.5. Fluorescein Sodium Micro lymphangiography
15.18.6. Ultrasound Imaging
15.18.7. ICG Lymphography
15.18.8. Bio impedance Analysis
15.18.9. Near-infrared Fluorescence Imaging
15.19. Argentina LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
15.19.1. Cardiovascular Diseases
15.19.2. Cancer
15.19.3. Inflammatory Diseases
15.19.4. Others
15.20. Argentina LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
15.20.1. Hospitals
15.20.2. Diagnostic Centers
15.20.3. Research and Academic Centers
15.20.4. Others
15.21. Rest of South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology
15.21.1. Lymphoscintigraphy
15.21.2. X-ray Lymphography
15.21.3. Computed Tomography
15.21.4. Magnetic Resonance Imaging
15.21.5. Fluorescein Sodium Micro lymphangiography
15.21.6. Ultrasound Imaging
15.21.7. ICG Lymphography
15.21.8. Bio impedance Analysis
15.21.9. Near-infrared Fluorescence Imaging
15.22. Rest of South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type
15.22.1. Cardiovascular Diseases
15.22.2. Cancer
15.22.3. Inflammatory Diseases
15.22.4. Others
15.23. Rest of South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user
15.23.1. Hospitals
15.23.2. Diagnostic Centers
15.23.3. Research and Academic Centers
15.23.4. Others
15.24. South America LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis
15.24.1. By Technology
15.24.2. By Disease Type
15.24.3. By End-user
15.25. PEST Analysis
15.26. Key Trends
15.27. Key Developments
16. Company Profiles
16.1. Market Share Analysis, By Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players By price, presence, market share, Disease Type, and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A By Regions, Investment and Disease Type
16.2.3.2. M&A Key Players, Forward Integration and Backward Integration
16.3. Company Profiles: Key Players
16.3.1. Siemens Healthineers
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. GE Healthcare
16.3.3. Stryker Corporation
16.3.4. Mindray Medical International, Ltd.
16.3.5. Philips
16.3.6. Canon, Inc
16.3.7. Shimazdu Corporation
16.3.8. Fluoptics United Imaging Healthcare Co, Ltd
16.3.9. Hitachi Ltd
16.3.10. Esaote
16.3.11. SpA
16.3.12. Neusoft Corporation
16.3.13. Mindray Medical International Ltd
16.3.14. Mitaka, Inc
16.3.15. Curadel, LLC
16.3.16. ImpediMed Ltd
16.3.17. Others